InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,812.96
(
0.03%
)
Post# of 797
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

XenaLives

Send PM Follow Ignore
Followers 481
Posts 60467
Boards Moderated 18
Alias Born 09/20/2001

XenaLives

Member Level

Re: None

Monday, 03/20/2017 8:44:27 AM

Monday, March 20, 2017 8:44:27 AM

Post# of 797
Ipatasertib is P2, partnered with Genentech. Apparently it was chosen because of Zaida's unusual genetic mutation. Given the pipeline I see no reason why this news should trash the share price, but the Market can make a mountain out of a molehill

http://www.arraybiopharma.com/product-pipeline



In Peace, In War

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ARRY News
More ARRY News
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!